Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462196 · ClinicalTrials.gov registry record
Natural History of Depression, Bipolar Disorder and Suicide Risk
A clinical trial of Suicide and Self Injurious Behavior, sponsored by National Institute of Mental Health (NIMH).
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06462196: Recruiting study of Suicide and Self Injurious Behavior, sponsored by National Institute of Mental Health (NIMH).
NCT06462196 is a study of Suicide and Self Injurious Behavior that is actively recruiting participants, run by National Institute of Mental Health (NIMH). The registered enrollment target is 500 participants, below the 6,984-participant average among 92 other Suicide trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06462196, a study of Suicide and Self Injurious Behavior, is actively recruiting participants, sponsored by National Institute of Mental Health (NIMH).
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide. People 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254. This study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time. Participants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation....
Primary Outcome
Depression rating scale
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2030-06-01 |
What NCT06462196 shows while recruiting
NCT06462196 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 6,984-participant average among 92 other Suicide trials with a reported enrollment target (93% lower).
The record links to 10 conditions, with Suicide appearing as the primary indexed condition, and to 0 interventions.
NCT06462196 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06462196 about?
NCT06462196 is a clinical study titled "Natural History of Depression, Bipolar Disorder and Suicide Risk". Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for ...
What is the current status of trial NCT06462196?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-09-09. Estimated completion is 2030-06-01.
What conditions does trial NCT06462196 study?
This clinical trial studies the following conditions: Suicide, Self Injurious Behavior, Physiological Effects of Drugs, Behavioral Symptoms, Peripheral Nervous System Agents.
Who is sponsoring clinical trial NCT06462196?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06462196 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06462196's enrollment target sits among peer trials
500 20th of 92 higher than 73 of 92 other Suicide trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Real-time Examination of Skills and Coping Use in Teen's Everyday Lives
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI